Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDLI Enforcement Conference In Brief

This article was originally published in The Tan Sheet

Executive Summary

Four signs an inspection is not going well: Firms undergoing an FDA inspection should be wary of problems if inspectors show up later every day during the process, says Raymond Bonner, a partner at Sidley Austin. During the first day of the Oct. 12-13 Food and Drug Law Institute conference in Washington, Bonner explained that inspectors who arrive later on subsequent inspection days "are probably not getting another round of pancakes," but rather are "coordinating with headquarters" on how to address issues they identified on previous days. Another sign an inspection is not going well is inspectors planning a re-inspection while conducting the initial audit, Bonner said. Other indications of problems are FDA dragging its feet on giving a firm an establishment inspection report and the agency not responding to requests to discuss a firm's response to a form 483 following an inspection. In cases where problems are likely, Bonner recommends firms engage with FDA immediately, "bring in a team that swarms the facility and jumps on" issues identified during the inspection and dedicate funds to correcting problems. Prompt response by firms could turn the confidence of FDA back in a company's favor, he said

You may also be interested in...

FDA Asks For Industry Input On Regulating Web And New Media Promotion

Drug firms may be one step closer to receiving FDA's guidance on online promotion with the agency's announcement of a public meeting on promoting products via "the Internet and social media tools.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts